We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.78%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.3B
AUM Growth
-$82M
Cap. Flow
-$615M
Cap. Flow %
-7.41%
Top 10 Hldgs %
34.19%
Holding
170
New
23
Increased
24
Reduced
50
Closed
20

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$104M
2
CI icon
Cigna
CI
+$77.7M
3
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$73.5M
4
MOH icon
Molina Healthcare
MOH
+$62.4M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$56.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$125M
2
BIIB icon
Biogen
BIIB
+$88.7M
3
SEM
Select Medical
SEM
+$77.6M
4
MRK icon
Merck
MRK
+$75.8M
5
FOLD
Amicus Therapeutics
FOLD
+$74.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.81%
2 Financials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STIM icon
126
Neuronetics
STIM
$132M
$4.81M 0.06%
150,000
– –
VYNE icon
127
VYNE Therapeutics
VYNE
$4.66M 0.06%
+131
New +$4.04M
CPRX
128
DELISTED
Catalyst Pharmaceutical
CPRX
$4.17M 0.05%
+1,102,000
New +$3.45M
GWPH
129
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.63M 0.04%
21,000
– –
SNDX icon
130
Syndax Pharmaceuticals
SNDX
$1.69B
$3.53M 0.04%
437,000
– –
MGTX icon
131
MeiraGTx Holdings
MGTX
$1.08B
$3.44M 0.04%
+253,183
New +$2.74M
RLM
132
DELISTED
Realm Therapeutics plc American Depositary Shares
RLM
$3.05M 0.04%
+1,021,484
New +$4.38M
XFOR icon
133
X4 Pharmaceuticals
XFOR
$376M
$3.03M 0.04%
10,383
– –
IRWD icon
134
CALL
Ironwood Pharmaceuticals
IRWD
$604M
$2.77M 0.03%
179,100
– –
TSRO
135
DELISTED
TESARO, Inc.
TSRO
$2.63M 0.03%
67,281
– –
RDHL
136
Redhill Biopharma
RDHL
$4.26M
$2.52M 0.03%
285
-280
-50% -$2.28M
ADMS
137
DELISTED
Adamas Pharmaceuticals
ADMS
$2M 0.02%
+100,000
New +$2.35M
ANAB icon
138
PUT
AnaptysBio
ANAB
$1.52B
$2M 0.02%
+20,000
New +$1.66M
AFMD
139
DELISTED
Affimed
AFMD
$1.42M 0.02%
32,665
– –
SRRA
140
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.3M 0.02%
19,178
-12,500
-39% -$1.13M
BLRX
141
BioLineRX
BLRX
$12.3M
$1.11M 0.01%
1,731
– –
SCTL
142
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$763K 0.01%
119,703
– –
ALIM
143
DELISTED
Alimera Sciences
ALIM
$245K ﹤0.01%
16,667
– –
XYLO
144
DELISTED
Xylo Technologies
XYLO
$51K ﹤0.01%
375
– –
ACAD icon
145
Acadia Pharmaceuticals
ACAD
$4.46B
– –
-4,282,400
Closed -$65.4M
ALNY icon
146
Alnylam Pharmaceuticals
ALNY
$38.6B
– –
-1,265,966
Closed -$125M
AMED
147
DELISTED
Amedisys
AMED
– –
-171,100
Closed -$14.6M
AUPH icon
148
Aurinia Pharmaceuticals
AUPH
$1.92B
– –
-167,419
Closed -$943K
BMRN icon
149
CALL
BioMarin Pharmaceuticals
BMRN
$12B
– –
-70,000
Closed -$6.59M
INCY icon
150
Incyte
INCY
$25.2B
– –
-438,000
Closed -$29.3M
3 4 5
6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2018 Portfolio in Review

As of Q3 2018, OrbiMed held 170 positions worth $8.3B, down 0.98% from $8.38B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed withdrew a net $615M in Q3 2018, closing 20 positions and reducing 50 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $125M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Principia Biopharma Inc. Common Stock worth $76.1M.

  • OrbiMed's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 2,605,713 shares worth $76.1M.
  • OrbiMed added most to Humana in Q3 2018, an estimated $104M increase.
  • OrbiMed's biggest Q3 2018 reduction was Biogen, cutting an estimated $88.7M.
  • OrbiMed fully exited Alnylam Pharmaceuticals in Q3 2018, selling an estimated $125M.
  • OrbiMed's ten largest holdings make up 34% of its $8.3B portfolio in Q3 2018.
  • OrbiMed opened 23 new positions and closed 20 in Q3 2018.
  • OrbiMed's portfolio value fell 0.98% quarter-over-quarter to $8.3B.

Based on OrbiMed's 13F filing for Q3 2018, filed 14 Nov 2018.